{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-037575","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2023-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.824420+00:00","generated_at":"2026-06-09T21:50:33.046830+00:00","sec_items":["1.01","3.03","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PAVmed subsidiary Lucid Diagnostics raises $5M via Series A-1 Convertible Preferred Stock","bullets":["Lucid Diagnostics, majority-owned PAVmed sub, sold 5,000 shares of newly designated Series A-1 Convertible Preferred at $1,000/share.","Gross proceeds of $5.0 million from accredited investors; private placement closed October 18, 2023.","Certificate of Designation and Registration Rights Agreement filed by Lucid on Form 8-K; terms incorporated by reference."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-037575","json":"https://secwatch.observer/filing/0001493152-23-037575.json","markdown":"https://secwatch.observer/filing/0001493152-23-037575.md","text":"https://secwatch.observer/filing/0001493152-23-037575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315223037575/0001493152-23-037575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315223037575/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:50:33.046830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ecc2b64a5dfd57a1ffc981665999e65e58c574a","claim":"PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at aggregate gross proceeds to Lucid of $5.0 million (effective 2023-10-17).","evidence_excerpt":"Effective as of October 17, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors for the sale of 5,000 shares of newly designated Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series A-1 Preferred Stock ”), at a purchase price of $1,000 per share, for aggregate gross proceeds to Lucid of $5.0 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315223037575/0001493152-23-037575-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"aggregate gross proceeds to Lucid of $5.0 million"},{"label":"Effective","value":"2023-10-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}